PolyPid to Present SHIELD I Phase 3 Clinical Data at American College of Surgeons Clinical Congress 2023

PolyPid Ltd., a late-stage biopharma company focused on improving surgical outcomes, has announced that it will be presenting the SHIELD I Phase 3 clinical data for its lead product candidate, D-PLEX100, at the American College of Surgeons Clinical Congress 2023. The congress is scheduled to take place from October 22-25, 2023, in Boston, MA.

PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, combined with Active Pharmaceutical Ingredients (APIs), allows for the precise delivery of drugs at optimal release rates over extended periods, ranging from several days to months. D-PLEX100 is currently in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections.

The abstract of the presentation will be made available on PolyPid’s website, www.polypid.com, once the conference concludes. This presentation at the American College of Surgeons Clinical Congress 2023 highlights the company’s commitment to advancing surgical outcomes through innovative drug delivery solutions.

PolyPid is also actively exploring the potential of its OncoPLEX product candidate for the treatment of solid tumors, starting with glioblastoma. The company aims to leverage its expertise in controlled, prolonged-release therapeutics to address critical unmet medical needs.

For more information about PolyPid and its ongoing research and development efforts, please visit their website at http://www.polypid.com. Stay updated by following them on Twitter and LinkedIn.

Contact:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com